🚀 VC round data is live in beta, check it out!
Giant Biogene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Giant Biogene and similar public comparables like Hengan Group, e.l.f. Beauty, Unilever Indonesia, Procter & Gamble Hygiene and more.
Giant Biogene Overview
About Giant Biogene
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Founded
2021
HQ
Employees
1.8K
Website
Sectors
Financials (LTM)
EV
$3B
Giant Biogene Financials
Giant Biogene reported last 12-month revenue of $832M and EBITDA of $335M.
In the same LTM period, Giant Biogene generated $667M in gross profit, $335M in EBITDA, and $281M in net income.
Revenue (LTM)
Giant Biogene P&L
In the most recent fiscal year, Giant Biogene reported revenue of $812M and EBITDA of $368M.
Giant Biogene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $832M | XXX | $812M | XXX | XXX | XXX |
| Gross Profit | $667M | XXX | $667M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $335M | XXX | $368M | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 45% | XXX | XXX | XXX |
| EBIT Margin | 38% | XXX | 42% | XXX | XXX | XXX |
| Net Profit | $281M | XXX | $302M | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 37% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Giant Biogene Stock Performance
Giant Biogene has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Giant Biogene's stock price is $3.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 0.0% | XXX | XXX | XXX | $0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGiant Biogene Valuation Multiples
Giant Biogene trades at 3.2x EV/Revenue multiple, and 7.9x EV/EBITDA.
EV / Revenue (LTM)
Giant Biogene Financial Valuation Multiples
As of April 20, 2026, Giant Biogene has market cap of $4B and EV of $3B.
Equity research analysts estimate Giant Biogene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Giant Biogene has a P/E ratio of 13.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | 7.2x | XXX | XXX | XXX |
| EV/EBIT | 8.3x | XXX | 7.8x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | 4.0x | XXX | XXX | XXX |
| P/E | 13.7x | XXX | 12.8x | XXX | XXX | XXX |
| EV/FCF | 11.0x | XXX | 10.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Giant Biogene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Giant Biogene Margins & Growth Rates
Giant Biogene's revenue in the last 12 month grew by 13%.
Giant Biogene's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Giant Biogene's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Giant Biogene's rule of X is 69% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Giant Biogene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | (10%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 38% | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Giant Biogene Public Comps
See public comps and valuation multiples for other Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Giant Biogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Hengan Group | XXX | XXX | XXX | XXX | XXX | XXX |
| e.l.f. Beauty | XXX | XXX | XXX | XXX | XXX | XXX |
| Unilever Indonesia | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Hygiene | XXX | XXX | XXX | XXX | XXX | XXX |
| Proya Cosmetics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Giant Biogene M&A Activity
Giant Biogene acquired XXX companies to date.
Last acquisition by Giant Biogene was on XXXXXXXX, XXXXX. Giant Biogene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Giant Biogene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGiant Biogene Investment Activity
Giant Biogene invested in XXX companies to date.
Giant Biogene made its latest investment on XXXXXXXX, XXXXX. Giant Biogene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Giant Biogene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Giant Biogene
| When was Giant Biogene founded? | Giant Biogene was founded in 2021. |
| Where is Giant Biogene headquartered? | Giant Biogene is headquartered in China. |
| How many employees does Giant Biogene have? | As of today, Giant Biogene has over 1K employees. |
| Who is the CEO of Giant Biogene? | Giant Biogene's CEO is Jianya Yan. |
| Is Giant Biogene publicly listed? | Yes, Giant Biogene is a public company listed on HKEX. |
| What is the stock symbol of Giant Biogene? | Giant Biogene trades under 02367 ticker. |
| When did Giant Biogene go public? | Giant Biogene went public in 2022. |
| Who are competitors of Giant Biogene? | Giant Biogene main competitors are Hengan Group, e.l.f. Beauty, Unilever Indonesia, Procter & Gamble Hygiene. |
| What is the current market cap of Giant Biogene? | Giant Biogene's current market cap is $4B. |
| What is the current revenue of Giant Biogene? | Giant Biogene's last 12 months revenue is $832M. |
| What is the current revenue growth of Giant Biogene? | Giant Biogene revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Giant Biogene? | Current revenue multiple of Giant Biogene is 3.2x. |
| Is Giant Biogene profitable? | Yes, Giant Biogene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Giant Biogene? | Giant Biogene's last 12 months EBITDA is $335M. |
| What is Giant Biogene's EBITDA margin? | Giant Biogene's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of Giant Biogene? | Current EBITDA multiple of Giant Biogene is 7.9x. |
| What is the current FCF of Giant Biogene? | Giant Biogene's last 12 months FCF is $239M. |
| What is Giant Biogene's FCF margin? | Giant Biogene's last 12 months FCF margin is 29%. |
| What is the current EV/FCF multiple of Giant Biogene? | Current FCF multiple of Giant Biogene is 11.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.